These are notes from my senior on “dermatophytes resistance to antifun

+6 more

These are notes from my senior on “dermatophytes resistance to antifungals” but since i have never read the topic I can’t understand the topic from these notes can u help understand it

Reading File

analyse_media

Reading File

Finding Sources

Let me walk you through these notes step by step in plain language, since this is a fairly dense topic on antifungal resistance in dermatophytes (the fungi that cause ringworm, tinea, athlete's foot, etc.).

The big picture

Dermatophytes are fungi that need to break down keratin (the protein in skin, hair, nails) to survive - that's why they cause ringworm/tinea infections. This topic is about why some of these infections don't respond to standard antifungal drugs anymore - a growing problem, especially with terbinafine-resistant Trichophyton in India.

Page 1: Two types of "resistance" - don't confuse them

Your notes correctly separate two related but different ideas:

1. Clinical resistance - the infection doesn't clear even though you gave a drug that works fine in the lab (shows in-vitro activity) and dosed it adequately. In other words: the drug should work on paper, but the patient's infection isn't improving. This is a "real-world treatment failure."

2. Microbiological resistance - this is the lab-defined version. You test the fungus against the drug and measure the MIC (Minimum Inhibitory Concentration) - the lowest drug concentration that stops growth. If the MIC is higher than the established "breakpoint" for that drug, the organism is officially called resistant. This is further split into:

Intrinsic resistance: the organism was never susceptible to begin with, even before any drug exposure (example given: Candida krusei is naturally resistant to fluconazole - it never worked on this species).
Secondary/Acquired resistance: the fungus used to be susceptible, but became resistant after being exposed to the drug (this is the more worrying, evolving type).

Why clinical failure happens (the 4 categories of factors):

Fungal factors: reduced drug accumulation inside the cell, reduced binding affinity to its target, stress-response changes, biofilm formation
Host factors: immunosuppression, site of infection (e.g., nails are harder to treat than skin), how severe/extensive the infection is, how late treatment started
Environmental factors: temperature, moisture, hygiene (these affect fungal growth/persistence on skin)
Drug-related factors: whether the drug is fungistatic (only inhibits) vs fungicidal (kills), inadequate dosing, pharmacokinetics (how well the drug is absorbed/distributed), and drug-drug interactions

Page 2 & 3: The actual biological mechanisms of resistance (the core of the topic)

This is where it gets molecular. Five main mechanisms:

Mechanism 1 - Drug Efflux (pumping the drug back out) Fungal cells have pump proteins in their membrane that grab the antifungal drug and physically throw it back out of the cell before it can act - so intracellular drug levels never get high enough to work. The classic example is overexpression of ABC transporters (ATP-Binding Cassette superfamily) - these use energy from ATP to actively pump drugs out. Three transporter families involved: MDR, MRP (MDR-associated protein), and PDR (Pleiotropic Drug Resistance). Since blocking these pumps could restore drug sensitivity, researchers have tested efflux-pump inhibitors like domperidone-class agents on TBF (terbinafine)-resistant M. canis strains.

Mechanism 2 - Drug Detoxification Less well studied in fungi than in bacteria. When fungi are exposed to sub-lethal ("subinhibitory") drug concentrations, they switch on detox genes - producing more catalase, superoxide dismutase (SOD), peroxidases, and glutathione transferase/peroxidase. These enzymes neutralize the oxidative stress/toxic effects of the drug and protect the cell from dying. In T. rubrum specifically, esterase enzymes (different isoforms) participate in this detox and general stress response; two SAL-A genes are linked to terbinafine resistance. In Candida albicans, increased expression of the ERG11 gene drives azole resistance (this gene, importantly, also reappears in mechanism 5 below - it's the target enzyme itself being overproduced).

Mechanism 3 - Transcriptional modification of kinase genes Fungal cells respond to stress (including drug stress) by activating protein kinases (enzymes that add phosphate groups to control other proteins) - these kinases are themselves potential drug targets. In T. rubrum, several kinase genes get turned up or down when exposed to antifungals: MpkA, STE7, SPS1, pyridoxine kinase (mostly decreased), and CaMK (increased), while "Ser/Thr protein kinase" can go either way. This shows the fungus is actively rewiring its internal signaling in response to drug pressure.

Mechanism 4 - Fungal Heat Shock Proteins (HSPs) HSPs are "chaperone" proteins that help other proteins fold correctly, and they help with transcription, translation, and clumping/un-clumping of proteins - especially under stress. In T. rubrum, the genes for HSP90 and its master transcription factor HSF1 get switched on (upregulated) when exposed to terbinafine (tbf) and acriflavine. HSP90 is particularly important because in Candida albicans and Saccharomyces cerevisiae, it's directly linked to azole resistance - it helps stabilize the stress-response machinery that lets the fungus survive drug exposure. It's involved in both how "aggressive"/pathogenic the fungus is AND how susceptible it is to drugs.

Mechanism 5 - Mutations affecting target genes This is the classic "the drug's target itself changes so the drug can't bind it anymore" mechanism. Mostly affects enzymes involved in:

Ergosterol biosynthesis (ergosterol is the fungal equivalent of cholesterol, essential for the cell membrane) - mutations in ERG11 (encodes lanosterol 14-alpha-demethylase, the target of azole drugs; well documented in azole-resistant C. albicans) and squalene epoxidase (SE) (the target of terbinafine - this is the mutation your library search confirmed is behind terbinafine-resistant Trichophyton)
Cell wall biosynthesis - mutations in FKS genes (two "hotspots," FKS1 and FKS2) which affect echinocandin drugs (drugs that target the fungal cell wall, like caspofungin/micafungin)

Mechanism 6 - Structural elements i) Biofilms: complex communities of fungal cells stuck together and embedded in a self-made extracellular matrix (ECM) made of exopolysaccharide (EPS) - this is actually the most common way microbes grow in nature (not free-floating). Biofilms increase drug resistance through: structural complexity (drug can't penetrate), the ECM matrix acting as a physical barrier, metabolic heterogeneity (some cells are dormant/slow-growing and less vulnerable), and increased expression of efflux pump genes. This creates "persister cells" - a subpopulation that survives even high drug concentrations.

ii) Arthroconidia: spore-like structures produced when hyphae (fungal filaments) fragment. These are the main way dermatophyte infections spread person-to-person, and they're inherently more drug-resistant than the actively growing hyphal form (dormant structures are generally harder to kill).

Page 4: What to do about it (management/strategy)

Your notes say you should suspect resistance when a patient has: recurrent infection episodes, no response to first-line treatment, widespread/generalized involvement, or an atypical clinical picture. This matters because catching it early helps prevent spread within a household ("family members").

Five strategies to combat resistance:

Good skin hygiene - basic but reduces reinfection/spread
Prudent antifungal use - correct dose and correct duration (under-dosing or stopping early is a major driver of resistance)
Combination antifungals (topical + systemic together) - advantages: faster and more complete fungal killing, broader spectrum coverage, and reduced chance of resistance developing
Combining antifungals with non-antifungal drugs that have synergistic or helpful effects:
- Calcineurin inhibitors, PPIs, cholesterol-lowering agents, antiparasitics
- Cyclosporine specifically - increases susceptibility to antifungals through deletion/inhibition of drug efflux pumps (linking back to Mechanism 1)
Newer antifungals:
- Drugs pharmacologically similar to older ones but with lower MIC (more potent) - e.g., isavuconazole, micafungin
- Repurposing old compounds alongside a new drug for new indications - e.g., combining HSP90 inhibitors with azoles (this directly exploits Mechanism 4 - if you block HSP90, you strip away the fungus's stress-survival shield, making the azole work again)

How it all connects

Think of it as a fungal cell under siege by a drug, with 5 defense strategies: (1) pump the drug out, (2) chemically neutralize/detoxify it, (3) rewire internal stress signaling, (4) call in chaperone proteins (HSP90) to keep essential proteins functional under stress, and (5) mutate the drug's actual target so it doesn't bind anymore - plus (6) physically hide in biofilms or hardy spore forms. Management strategies mostly work by hitting these same points from the other side - e.g., blocking efflux pumps (cyclosporine) or blocking HSP90 to make old drugs work again.

This is consistent with standard microbiology references - for example, azole resistance via efflux pump upregulation and target enzyme overexpression, and terbinafine resistance via squalene epoxidase gene mutations, are both well documented (Medical Microbiology, 9th ed.; Tietz Textbook of Laboratory Medicine, 7th ed.).

If you want, I can make you a one-page summary diagram/flowchart of the 5 resistance mechanisms plus the 5 management strategies for quick revision - just let me know.

This is a shared conversation. Sign in to Orris to start your own chat.